Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

被引：0
|
作者：
Rita Nahta
Dihua Yu
Mien-Chie Hung
Gabriel N Hortobagyi
Francisco J Esteva
机构：
[1] Instructor at the Department of Breast Medical Oncology,Departments of Breast Medical Oncology and Molecular & Cellular Oncology
[2] Professor at the Departments of Surgical Oncology and Molecular and Cellular Oncology,undefined
[3] Professor in the Department of Molecular and Cellular Oncology,undefined
[4] Chairman and Professor in the Department of Breast Medical Oncology,undefined
[5] Director of the Breast Cancer Translational Research Laboratory and Associate Professor,undefined
[6] University of Texas MD Anderson Cancer Center,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite the impressive results seen in phase II trials of trastuzumab, many tumors that overexpress HER2 show resistance to the drug. Understanding the molecular mechanisms underlying primary or treatment-induced trastuzumab resistance is critical to improving the survival of patients with metastatic breast cancer with aggressive HER2 overexpressing tumors. This review discusses the novel therapeutic strategies that target the aberrant molecular pathways, and explains how these strategies could greatly improve the duration of response to trastuzumab.
引用
收藏
页码：269 / 280
页数：11
相关论文
共 50 条
  • [21] Cardiac Complications of HER2-Targeted Therapies in Breast Cancer
    Addetia K.
    DeCara J.M.
    Current Treatment Options in Cardiovascular Medicine, 2016, 18 (6)
  • [22] EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
    Bao, Yi
    Oguz, Gokce
    Lee, Wee Chyan
    Lee, Puay Leng
    Ghosh, Kakaly
    Li, Jiayao
    Wang, Panpan
    Lobie, Peter E.
    Ehmsen, Sidse
    Ditzel, Henrik J.
    Wong, Andrea
    Tan, Ern Yu
    Lee, Soo Chin
    Yu, Qiang
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [23] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Park, Juin
    Kang, Sun Kyoung
    Kwon, Woo Sun
    Jeong, Inhye
    Kim, Tae Soo
    Yu, Seo Young
    Cho, Sang Woo
    Chung, Hyun Cheol
    Rha, Sun Young
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [24] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
  • [25] Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park
    Sun Kyoung Kang
    Woo Sun Kwon
    Inhye Jeong
    Tae Soo Kim
    Seo Young Yu
    Sang Woo Cho
    Hyun Cheol Chung
    Sun Young Rha
    Scientific Reports, 13
  • [26] HER2-targeted therapy is changing
    Matsumura, Noriomi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (04): : 325 - 325
  • [27] HER2-Targeted Therapy in Osteosarcoma
    Gill, Jonathan
    Hingorani, Pooja
    Roth, Michael
    Gorlick, Richard
    CURRENT ADVANCES IN OSTEOSARCOMA: CLINICAL PERSPECTIVES: PAST, PRESENT AND FUTURE, 2ND EDITION, 2020, 1257 : 55 - 66
  • [28] HER2-targeted therapies — a role beyond breast cancer
    Do-Youn Oh
    Yung-Jue Bang
    Nature Reviews Clinical Oncology, 2020, 17 : 33 - 48
  • [29] HER2-targeted therapies - a role beyond breast cancer
    Oh, Do-Youn
    Bang, Yung-Jue
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (01) : 33 - 48
  • [30] HER2-targeted therapy in colorectal cancer: a comprehensive review
    Benli, Yeliz
    Arikan, Helin
    Akbulut-caliskan, Ozge
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
12345